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ABSTRACT
Inhibition of the epidermal growth factor receptor (EGFR) is an
establishedtreatmentthatextendspatientsurvivalacrossavariety
of tumor types. EGFR inhibitors fall into twomain categories: anti-
EGFRmonoclonal antibodies, such as cetuximabandpanitumumab,
and first-generation tyrosine kinase inhibitors, such as afatinib,
gefitinib, and erlotinib. Skin reactions are themost common EGFR
inhibitor-attributable adverse event, resulting in papulopustular
(acneiform) eruptions that can be painful and debilitating, and
which may potentially have a negative impact on patients’quality
of life and social functioning, as well as a negative impact on
treatment duration. Shortened treatment duration can, in turn,
compromise antineoplastic efficacy. Similarly, appropriate man-
agement of skin reactions is dependent on their accurate grad-
ing; however, conventional means for grading skin reactions are
inadequate, particularly within the context of clinical trials.
Treating a skin reaction only once it occurs (reactive treatment
strategies) may not be the most effective management approach;
instead, prophylactic approaches may be preferable. Indeed, we
support the viewpoint that prophylactic management of skin
reactions should be recommended for all patients treated with
EGFR inhibitors. Appropriate prophylactic management could
effectively reduce the severity of skin reactions in patients treated
with EGFR inhibitors and therefore has the potential to directly
benefit patients and improve drug adherence. Accordingly, here
wereviewpublishedandstill-emergingdata,andprovidepractical
and evidence-based recommendations and algorithms regarding
the optimal prophylactic management of EGFR inhibitor-
attributable skin reactions.The Oncologist 2016;21:1483–1491
Implications for Practice: Epidermal growth factor receptor (EGFR) inhibitors extend patient survival across a variety of tumor
types.Themost common EGFR inhibitor-attributable adverse events are skin reactions. Prophylactic—rather than reactive—management
of skin reactions for all patients receiving EGFR inhibitors should be recommended because appropriate prophylaxis could effec-
tively reduce the severity of skin reactions; thus, the derivation of highly effectiveprophylactic strategies has the potential to directly
benefit patients. Accordingly, a reviewof the available data leads to practical and evidence-based recommendations and algorithms
regarding the optimal prophylactic management of EGFR inhibitor-attributable skin reactions.
INTRODUCTION
Inhibition of the epidermal growth factor receptor (EGFR) has
proven to be an effective treatment option in a variety of
cancers, including metastatic colorectal cancer (mCRC) [1],
squamous cell carcinoma of the head and neck (SCCHN) [2],
non-small cell lung cancer (NSCLC) [3], and pancreatic cancer
[4], leading to increased overall survival. The purpose of this
review is to provide practicing oncologists with a concise, up-
to-date, and accessible set of recommendations for pro-
phylactically managing skin reactions resulting from EGFR
inhibitor-based therapy. By summarizing key findings on the
topic and compiling them into an updated, convenient
algorithm, we endeavor to benefit patients via facilitating
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improved clinical management of their EGFR inhibitor-
attributable skin reactions. Broadly speaking, EGFR inhibitors
can be categorized as either monoclonal antibodies (mAbs) or
tyrosine kinase inhibitors (TKIs).We will focus on those mAbs
(cetuximabandpanitumumab)and first-generationTKIs (afatinib,
erlotinib, and gefitinib) for which data regarding prophylactic
management of their associated skin reactions are already
available. Thus, although we appreciate the clinical impor-
tance of the mAb necitumumab and the TKIs lapatinib and
osimertinib, these newer EGFR inhibitors will not be specif-
ically discussed here.
mAbs, such as cetuximab and panitumumab, function
by binding to the EGFR receptor, preventing endogenous li-
gand binding and thereby dampening downstream signaling.
Cetuximab is approved for the first- and later-line treatment
of patients with RAS wild-type mCRC and locally advanced or
recurrent/metastatic SCCHN [1, 2, 5]. In contrast, panitumumab
is approved only for the first- and later-line treatment of
patients with RAS wild-type mCRC [6], because no survival
benefit has been demonstrated for patients with either locally
advancedor recurrent/metastatic SCCHN[7, 8].Althoughboth
panitumumab and cetuximab aremAbs that target EGFR, they
are immunologically distinct (IgG2 vs. IgG1, respectively) and
have somewhat different binding sites on the EGFR; thus,
they may not be identical in their actions. Notably, in vitro
studies suggest that induction of antibody-dependent cel-
lular cytotoxicity is associated with cetuximab, but not with
panitumumab.
First-generation TKIs, such as afatinib, erlotinib, and
gefitinib, bind to the kinase domain of EGFR, preventing its
phosphorylationandblockingdownstreamsignaling cascades.
Afatinib is approved for the first-line treatment of metastatic
NSCLC [9]. Erlotinib is approved for maintenance and second-
line treatment of locally advanced and metastatic NSCLC [10,
11], as well as the first-line treatment, in combination with
gemcitabine, of patients with locally advanced, unresectable,
or metastatic pancreatic cancer [4]. Gefitinib is approved for
the first-line treatment of patients with EGFR mutation-
positive metastatic NSCLC [12, 13].
Although efficacious across a wide variety of tumor types,
EGFR inhibitors also possess a predictable and manageable
adverse event (AE) profile. The most commonly reported AE
for both EGFR-targeting mAbs and first-generation TKIs is
acneiform rash, which is typically mild or moderate, but may
be severe in up to 18% of patients [14, 15]. Some believe that
the incidence and severity of rash may be worse in patients
treated with anti-EGFR mAbs versus first-generation TKIs
[16–20]; however, there are no available data to suggest that
themanagement of EGFR inhibitor-attributable skin reactions
differs notably between the various mAbs and first-generation
TKIs. Although anecdotal evidence has suggested that
panitumumab-associated skin reactions often occur more
frequently than those attributable to cetuximab, investigators
have foundthat the incidenceofAEsofanygradeandgrade3/4
AEs were similar between cetuximab- and panitumumab-
treated patients with mCRC in the randomized, third-line,
monotherapy ASPECCT study, the only head-to-head trial
comparing panitumumab and cetuximab. Of particular in-
terest in ASPECCT, 13% of patients treated with panitumumab
and10%of those treatedwith cetuximab developed grade3/4
skin reactions [21, 22]. Furthermore, cetuximab-associated
[23] and panitumumab-associated [24] skin reactions gener-
ally start within the first 3 weeks of initiating treatment for
mCRC.
Some believe that the incidence and severity of rash
may be worse in patients treated with anti-EGFR
mAbs versus first-generation TKIs; however, there are
no available data to suggest that the management
of EGFR inhibitor-attributable skin reactions dif-
fers notably between the various mAbs and first-
generation TKIs.
The development of skin reactions often follows a
predictable time course during therapy. Patients usually
experience edema and erythema during the first weeks of
treatment, followed by papulopustular (acneiform) eruptions
and crusting; later effects include paronychia and fissure [25,
26]. Skin reactions are transient, abating after the completion
of therapy, although postinflammatory changes (erythema
or pigmentation) may persist. As discussed in greater detail
below, clinical pathogenesis of skin reactions is assayed ac-
cording to various guidelines, each with unique strengths and
weaknesses; however, a simple, straightforward, and accurate
evaluation of the severity of skin reactions has not yet been
established.
Because EGFR inhibitor-related skin reactions can poten-
tially be painful and disfiguring, the occurrence of skin tox-
icities may negatively impact quality of life (QoL) and social
functioning. For example, in one study of 283 patients who
received targeted or nontargeted therapies, patients com-
pleted the Skindex-16 questionnaire, a dermatologic-specific
QoL evaluation of symptoms, emotions, and function. The
authors found that patients receiving targeted therapies had
significantly poorer symptom, emotion, and function sub-
scores on the Skindex-16 questionnaire, relative to those
receiving nontargeted therapies [27]. Similarly, findings from
theCancer and LeukemiaGroupB/SouthwestOncologyGroup
80405 trial suggested that, although overall QoL was
comparable between treatment arms, dermatologic-related
QoL was worse in patients with mCRC treated with che-
motherapy plus cetuximab versus patients treated with che-
motherapy plus bevacizumab [28]. At present, it seems
prudent to conclude that skin reactions appear to lead to a
negative impact on QoL, but our methods for capturing this
impact are highly variable in their effectiveness [6, 29–31]. Of
interest, the development of a new Functional Assessment of
Cancer Therapy questionnaire specific for EGFR inhibitor-
attributable skin reactions may aid in unequivocally resolving
the impact of skin reactions on patients’ QoL and social
functioning [32–37].
EGFR inhibitor-related skin reactions can also potentially
impact treatment duration, leading to treatment interruptions
and/or early cessation of therapy. More specifically, in cases
where a patient’s skin toxicity reaches grade 3 or higher on the
National Cancer Institute Common Terminology Criteria for
Adverse Events version 4.0 (NCI CTCAE v4.0) scale, physicians
can choose to lower the dose of the drug, temporarily interrupt
©AlphaMed Press 2016
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treatment, or terminate EGFR inhibitor therapy entirely [38].
Furthermore, patients may request to discontinue treatment
because of skin reactions resulting from therapy [10]. Because
patients aged less than50 years aremore likely to experience a
negative emotional effect from dermatological AEs, they may
face a higher risk of reduced efficaciousness of EGFR inhibitors
due to treatment interruptions and/or discontinuation [27, 39].
The most common treatment for EGFR inhibitor-related
skin reactions is the oral or topical application of tetracycline-
family antibiotics and corticosteroids, alone or in combination
with moisturizers and sunscreen [40–48]. These therapeutics,
which include doxycycline and minocycline, are commonly
usedtotreatacneiformrashandhelp reduce its symptoms.The
implementation of this care has historically only been reactive
to (i.e., subsequent to) development of the skin reaction;
however, as outlined in greater detail below, we espouse the
viewpoint that prophylactic management of skin reactions
should be recommended for all patients treated with EGFR
inhibitors. Indeed, appropriate prophylactic management could
effectively reduce the severity (although perhaps not inci-
dence) of skin reactions in patients treated with EGFR in-
hibitors, and therefore has the potential to directly benefit
patients and improve drug adherence. Reactive management
of EGFR inhibitor-associated skin reactions has been reviewed
extensively elsewhere [49–52] and will not be discussed here;
instead, we will focus on optimal deployment of prophylactic
measures to combat EGFR inhibitor-attributable skin reactions.
MATERIALS AND METHODS
When developing this nonsystematic review article, we
searched PubMed and American Society of Clinical Oncology
and European Society forMedical Oncologymeeting abstracts
to identify relevant studies. The search window encompassed
January 2004–January 2016; search terms included “EGFR in-
hibitorskin reactions,”“cetuximabskinreactions,”“panitumumab
skin reactions,” “afatinib skin reactions,” “erlotinib skin
reactions,” “gefitinib skin reactions,” “prophylactic care of skin
reactions,” and “skin reaction algorithms.” Priority was granted
to randomized clinical trials.Therewere no formal inclusion or
exclusion criteria, and the outputs of our searches were hand
curated. No unpublished material is included in this review
article.
Methods for Grading Skin Reactions
A major issue that complicates the proper management of
EGFR inhibitor-associated skin reactions—particularly in the
clinical trial setting—is that conventional means for grading
skin reactionsare inadequate.Onekey issueconcerns theneed
for a clear definition as to what constitutes a “skin reaction,”
becausemany subcategories of this broad termaresometimes
included, and this can vary among studies.
In this review, we will discuss three methods for grading
skin reactions: the NCI CTCAE v4.0, the Multinational Associa-
tion of Supportive Care in Cancer (MASCC) EGFR Inhibitor Skin
Toxicity Tool (MESTT©), and a three-part system suggested by
Wollenberg et al. [53]. Each of these systems will be described
below, along with its limitations.
One method for grading skin reactions is the NCI CTCAE
v4.0, which defines acneiform rash as a disorder characterized
by an eruption of papules and pustules, typically appearing on
the face, scalp, upper chest, and back. Skin reactions can be
categorized as grade 1–5 per this scoring system (Table 1).
A key issue with the NCI CTCAE v4.0 system is that “the rule
of 9”—which relates to the percentage of the body that is
affected—dictates that even locally severe rashes could po-
tentially be scored very low on the scale (grade 1/2), because
the area typically affected by rash would not reach the 30%
of body surface area (BSA) required by the current guidelines
to be scored as grade 3 or higher. For example, face-only rash
(even if severe, disfiguring, and/or having an impact on
patients’ lives) tends to be graded no higher than grade 1
(although this rash can still be categorized as grade3 in situations
in which self-care in activities of daily living is limited). Overall,
although the CTCAE scale allows for the flexibility of upgrading
an AE beyond the grade dictated by affected BSA guidelines,
this decision is left up to the discretion of the physician, which
can create inconsistencies.
A second skin-reaction grading system is the MESTT. This
method for grading skin reactions takes into consideration
patient-reported data, such asQoL, and also includes time and
effect on therapydoseof the experiencedAEs.MESTT includes
guidelines pertaining to papulopustular eruption, nail changes,
erythema, pruritus, xerosis, hair changes, flushing, telangiectasia,
and hyperpigmentation. However, the MESTT system is overly
complex,with 17 possible evaluablemeasures,making it difficult
for physicians to complete the evaluation in routine clinical
practice, even within the context of a clinical trial.
Finally, a third method for grading skin reactions is the
three-part system proposed by Wollenberg et al. [53]. This
scoring system takes into account the NCI CTCAE score on the
body surface, the percentage of skin involvement on the
face (which is easily ascertained), and a readily accessible
composite of five items of information on the most highly
affected region of the body. Notably, the three-part system is
Table 1. NCI CTCAE v4.0 grading criteria
Grade Symptoms
1 • Papules and/or pustules covering,10% BSA, which
may or may not be associated with symptoms of
pruritis and tenderness
2 • Papules and/or pustules covering 10%–30% BSA,
whichmayormaynot be associatedwith symptomsof
pruritis and tenderness
• Associated with psychological impact
• Limiting instrumental ADL
3 • Papules and/or pustules covering.30% BSA, which
may or may not be associated with symptoms of
pruritis and tenderness
• Limiting self-care ADL
• Local superinfection, with oral antibiotics indicated
4 • Papules and/or pustules covering any percentage
BSA, which may or may not be associated with
symptoms of pruritis and tenderness and are
associated with extensive superinfection, with i.v.
antibiotics indicated
• Life-threatening consequences
5 • Death
Abbreviations: ADL, activities of daily living; BSA, body surface area; NCI
CTCAE v4.0, National Cancer Institute Common Terminology Criteria for
Adverse Events, Version 4.0.
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Table 2. Relevant studies
Publication Indication EGFR inhibitor
Treatment arms
FindingArm 1 Arm 2 Arm 3
Jatoi, 2008 [40] Lung (51%) Cetuximab (38%) Tetracycline
(500 mg)
(n5 31)
Placebo (n5 30) — • Tetracycline did not
lessen incidence (70%
vs. 76%, p5 .61).
Gastrointestinal
(26%)
Gefitinib (13%) • Severity at week 4
may have been
decreased with
tetracycline
(physician-reported
grade 2 skin reactions:
17% vs. 55%, p5 .009),
but by week 8, 44% of
patients had left the
trial, preventing
meaningful evaluation
at this time point.
Other (23%) Other (49%) • Tetracycline
improved some QoL
measures.
Jatoi, 2011 [41] Lung (25%) Cetuximab (65%) Tetracycline
(500 mg)
(n5 33)
Placebo (n5 32) — • Tetracycline did not
lessen incidence
comparedwith placebo
(82% vs. 75%, p5 .56).
Gastrointestinal
(60%)
Gefitinib (2%) • Tetracycline did not
decrease severity (52%
vs. 44%, p5 .62).
Other (15%) Other (34%) • QoL was comparable
between treatment
arms.
Scope, 2007 [42] mCRC Cetuximab Minocycline
(n5 24)
Placebo (n5 24) — •Minocycline
significantly decreased
moderate-to-severe
itch over placebo (20%
vs. 50%, p5 .05).
•Minocycline trended
toward a decreased
incidence of grade. 2
skin reactions (20% vs.
42%, p5 .13).
Deplanque,
2016 [43]
NSCLC Erlotinib Doxycycline
(100 mg)
No treatment — • Doxycycline reduced
folliculitis over
untreated patients
(71% vs. 82%, p5 .117)
• Patients receiving
doxycycline had a
reduced severity of skin
reactions (grade 1/2/3/
4 NCI CTCAE were 61%/
35%/4%/0% and 18%/
62%/18%/2%,
respectively, p, .001).
Lacouture,
2016 [44]
mCRC Panitumumab Preemptive
treatment
(moisturizers,
sunscreen,
topical steroid
[hydrocortisone
1%], and
doxycycline
[100 mg])
(n5 48)
Reactive
treatment
(physician
determined)
(n5 47)
— • Incidenceofgrade.2
skin reactions was
decreased with
preemptive treatment
comparedwith reactive
treatment (29% vs.
62%).
• Preemptive
treatment was
associated with a small
change in QoL
measurements over
the courseof treatment
(at week 3: 1.3 vs. 4.2).
(continued)
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well suited for clinical trials and perhaps also for routine clini-
cal practice; for example, it is currently being evaluated along-
side the NCI CTCAE v4.0 system in two phase III clinical trials
(NCT01345526 and NCT01668498). Such studies may aid in
furtherestablishing the reproducibility andvalidityof this tool.
The semiquantitative nature of the Wollenberg et al. system
maybeperceivedassomewhat limiting, andsomemayfindthe
three-part, five-component structure to be complex; how-
ever, we believe that this system—which addresses the
whole body surface and skin involvement of the face, and
describes the type of skin toxicity in a semiquantitative
manner from merely five semiquantitative evaluations—is
a comprehensive and user-friendly tool to utilize when
evaluating dermatologic AEs because most components,
such as color intensity or degree of pustulation, can be
determined quickly via visual assessment [53].
Published Evidence Regarding Antibiotic-Based
Prophylactic Management of Skin Reactions Induced
by EGFR Inhibitors in Patients With Solid Tumors
A number of studies have been performed to evaluate the
prophylactic management of EGFR inhibitor-related skin
reactions using tetracycline-family antibiotics, often in con-
junction with topical approaches [40–48]. In a variety of
Table 2. (continued)
Publication Indication EGFR inhibitor
Treatment arms
FindingArm 1 Arm 2 Arm 3
Melosky,2015[45] NSCLC Erlotinib Prophylactic
minocycline
(100 mg)
(n5 50)
Reactive
minocycline
(n5 50)
No treatment
(n5 50)
• Prophylactic
minocycline did not
reduce the overall
incidence of skin
reactions over reactive
and no treatment (84%
incidence in all three
arms); however, grade
3 skin reactions
occurred more
frequently in the
no-treatment arm (vs.
prophylactic or reactive
treatment arms).
• Prophylactic
minocycline
significantly
lengthened the time to
the most severe grade
of skin reactions.
Arrieta, 2015 [46] NSCLC Afatinib Preemptive
tetracycline
(250 mg)
Reactive
treatment
— • Tetracycline reduced
incidence of any grade
skin reactions over
reactive treatment
(44.5% vs. 75.6%,
p5 .046).
• Tetracycline reduced
severity of grade$ 2
skin reactions over
reactive treatment
(15.6 vs. 35.6%, p5
.030).
Kobayashi,
2015 [47]
mCRC Panitumumab Preemptive skin
moisturizers,
sunscreen,
topical steroid,
and minocycline
(100 mg)
(n5 47)
Reactive
treatment (skin
moisturizers)
(n5 48)
— • Incidenceofgrade.2
skin reactions was
decreased with
preemptive treatment
comparedwith reactive
treatment (21.3% vs.
62.5%, p, .001).
• Double-blind central
review was performed
by a dermatologist.
Yamada, 2015 [48] mCRC Panitumumab Preemptive oral
minocycline in
combination
with skin
treatment using
moisturizer
(n5 25)
Reactive oral
minocycline in
combination
with skin
treatment using
moisturizer
(n5 13)
— • Incidenceofgrade$2
skin reactions was
significantly lower in
the preemptive vs.
reactive group (44.0%
vs. 84.6%; p5 .04).
Abbreviations: AE, adverse event; EGFR, epidermal growth factor receptor; mCRC, metastatic colorectal cancer; NCI CTCAE, National Cancer Institute
Common Terminology Criteria for Adverse Events; NSCLC, non-small cell lung cancer; QoL, quality of life.
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indications, including mCRC and NSCLC, prophylactic treatment
with tetracycline-class therapeutics (doxycycline, minocycline,
etc.) significantly reduced theseverityof skin reactions.However,
despite a reduction in their severity, it should be noted that a
reduction in the incidence of all grades of skin reaction was not
always observed (Table 2).
The exceptions to this finding of reduced severity of skin
reactions with prophylactic intervention were two studies
performedby Jatoi etal. [40, 41]. In theiroriginal trial, Jatoi etal.
noted thattetracyclinemay reduce theseverityofskin reactions
when given proactively, but their conclusions were potentially
compromised by the number of patients who dropped out of
the study; in a follow-up study that includednewdata, aswell as
apoolingof thepreviously collectedprospectivedata alluded to
above, the authors determined that tetracycline treatment
did not significantly reduce the incidence or severity of skin
reactions [40, 41]. This inconsistency may be attributable to
imbalances stemming from the multiple tumor types simulta-
neously examined (lung, gastrointestinal, and other sites) com-
pared with the single indications evaluated by the other trials
cited above. Furthermore, the Jatoi et al. trial evaluated
cetuximab, gefitinib, and other EGFR inhibitors, rather than
focusing on a single therapeutic agent. Finally, these studies
may have been confounded by the utilization of a nonoptimal
dose of tetracycline.
Consequently, the preponderance of the available evidence
establishes that treatmentwith tetracyclines reduces the sever-
ity of skin reactions when administered prophylactically.
Recommendations andAlgorithms for theProphylactic
Management of Skin Reactions Induced by EGFR
Inhibitors in Patients With Solid Tumors
With improved management of skin reactions, patients may
experience an improved QoL and avoid treatment-related
Figure 1. Recommendations for the prophylactic management of skin reactions induced by EGFR inhibitors: general basic skin care
recommendations for theearlyphase (A)andspecificprophylaxis recommendations foracne-like rash (B), startingwith the firstcetuximab
dose.Levelofevidenceandgradesof recommendations reflectthe followingscoringsystem:Levelsofevidenceareas follows: IA,evidence
frommeta-analysis of randomized controlled trials; IB, evidence fromat least one randomized controlled trial; IIA, evidence fromat least
one controlled study without randomization; IIB, evidence from at least one other type of quasi-experimental study; III, evidence from
nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; and IV, evidence from
expert committee reportsoropinionsorclinical experienceof respectedauthorities, orboth.Gradesof recommendationareas follows:A,
directly basedon level I evidence; B, directly basedon level II evidenceorextrapolated recommendations from level I evidence; C, directly
based on level III evidence or extrapolated recommendations from level I or II evidence; and D, directly based on level IV evidence or
extrapolated recommendations from level I, II, or III evidence.
Abbreviations: DAC, Deutscher Arzneimittel-Codex; LOE, level of evidence.
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lapses in EGFR-inhibitor administration (which could, in turn,
lead to decreased efficacy). Although commonly deployed,
reactive management of skin reactions often occurs too late,
indicatingthattreatmentalgorithmswouldbemoresuccessful
if they incorporated prophylactic care. In a recent paper from
Dascalu et al. [54], the authors evaluated the effect of
prophylactic versus reactive treatment of skin reactions in
patients withmCRC treated with cetuximab or panitumumab.
Although overall survival was similar between the two groups,
this merely underscores the importance of optimizing pro-
phylactic intervention practices [54].
Although commonly deployed, reactivemanagement
of skin reactions often occurs too late, indicating that
treatmentalgorithmswould bemore successful if they
incorporated prophylactic care.
Although grading scales are important in the implementa-
tion and evaluation of clinical trials, they are less useful in the
day-to-day setting, where physicians are more likely to be
evaluating skin reaction severity with the sole objective of
treating it appropriately. Therefore, treatment algorithms are
ofmorepractical use inclinical practice thanaregrading scales.
Macdonald et al. previously published an algorithm [52] in
which they proposed preventative care (including topical
steroids, sunscreen, and systemic tetracycline antibiotics) for
patients treatedwith cetuximab, panitumumab, erlotinib, and
gefitinib. However, the authors noted that prophylactic tet-
racycline may not diminish papulopustular eruptions, citing
Jatoi et al. [41] (the limitations of which were discussed
earlier). Another study showed that preventative sunscreen
use did not prevent or attenuate eruptions [55].
In light of the data cited above, which suggest that
prophylactic care can potentially reduce the severity of skin
reactions by twofold or greater, we provide the following
evidence-based recommendations for the prophylactic man-
agement of skin reactions induced by EGFR inhibitors. Starting
with the first EGFR-inhibitor dose, the application of pro-
phylactic basic skin care can prevent and reduce the severity
and extent of skin reactions. General recommendations for
basic daily regimens involving gentle cleansing, skin care, and
sunlight protection are summarized in Figure 1A, as is a list of
activities that should be avoided when possible.
Specific evidence-based prophylactic recommendations
for the management of EGFR inhibitor-induced acne-like rash
are summarized in Figure 1B. These include sunlight pro-
tection, skin care with hydrophilic cream (initial positive results
involving the prophylactic topical application of vitamin K
cream have been reported [56–58]; confirmatory data are
currently being sought in a German, randomized, multicenter
phase II study), and oral antibiotics with doxycycline (100–200
mg/day for $8 weeks) or minocycline (100 mg/day for $8
weeks). Antibiotic administration should begin no later than
the first day of EGFR-inhibitor treatment. The most common
potential adverse effects of tetracyclines are sensitivity of skin
to sunlight (rare with minocycline), cramps or burning of the
stomach, and diarrhea; minocycline has also been reported to
cause dizziness, light-headedness, or unsteadiness.
Additionally, we propose an opinion-based algorithm for
managing patients who received prophylactic treatment, but
whoneverthelessexperiencedskin reactions in response toEGFR
inhibitor-based therapy (Fig. 2). In brief, in accordance with the
findings of the STEPP trial [44], patients whose skin reactions are
either unaffected or worsen with the application of twice-daily
topical antibiotics are recommended to receive twice-daily
topical corticosteroids. In the event that the patients’ skin
reactions still do not improve, options include dose reduction
accordingtothesummaryofproductcharacteristics,consultation
with a dermatologist, or possible administration of isotretinoin
(and concomitant discontinuation of oral antibiotics).
Future Perspective
Additional trial data are soon anticipated. Enrollment is now
completed for the EVITA (NCT01345526) and AIO-LQ-0110
(NCT01668498) trials, which are investigating the addition of
Figure 2. Proposed algorithm for managing patients who experience skin reactions in response to EGFR inhibitor-based therapy.
Abbreviations: DAC, Deutscher Arzneimittel-Codex; EGFR, epidermal growth factor receptor.
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vitamin K to doxycycline prophylaxis and the substitution of
doxycycline by erythromycin cream, respectively. Another
study (NCT01931150), which is investigating topical dapsone
for cetuximab-induced skin reactions, is also ongoing.
Furthermore, results supporting the prophylactic use of antibi-
otics in conjunction with dacomitinib were presented at MASCC
2015, and full publication is eagerly awaited. Also encouraging
are findings emanating from the reactive deployment of epi-
dermal growth factor ointment in patients experiencing erlotinib-
related skin reactions [59], a reactive management strategy that
could potentially also prove useful in the prophylactic setting.
Another important topic for future research is the current
dearth of information regarding biomarkers that are possibly
predictiveofvulnerability to thedevelopmentof skin reactions
(either their incidence or severity). The elucidation of such
biomarkers could aid in identifying patients for whomaggressive
prophylactic treatment is most imperative.
CONCLUSION
Inhibition of EGFR is an established treatment that extends
patient survival across a variety of tumor types. Skin reactions
are the most common EGFR inhibitor-attributable AE and can
be painful and debilitating, potentially having a negative impact
on patients’QoL and social functioning.Moreover, skin reactions
can cause a negative impact on treatment duration; shortened
treatmentdurationcan, inturn,compromiseefficacy.Weespouse
the viewpoint that prophylactic management of skin reactions
should be recommended for all patients treated with EGFR
inhibitors. Indeed, appropriate prophylactic management could
effectively reduce the severity (although perhaps not incidence)
of skin reactions in patients treated with EGFR inhibitors and
therefore has the potential to directly benefit patients.
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